Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 7/2006

01-06-2006

Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels

Authors: Ryuichi Kita, Seigo Takamatsu, Toru Kimura, Hiroyuki Kokuryu, Yukio Osaki, Naomi Tomono

Published in: Journal of Gastroenterology | Issue 7/2006

Login to get access
Metadata
Title
Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels
Authors
Ryuichi Kita
Seigo Takamatsu
Toru Kimura
Hiroyuki Kokuryu
Yukio Osaki
Naomi Tomono
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 7/2006
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-006-1831-0

Other articles of this Issue 7/2006

Journal of Gastroenterology 7/2006 Go to the issue

Case report

Intraductal tubular carcinoma in an adenoma of the main pancreatic duct of the pancreas head

Editorial

Hiatal hernia and gastroesophageal flap valve as diagnostic indicators in patients with gastroesophageal reflux disease

Editorial

Treatment of functional dyspepsia: where to go and what to do

OriginalPaper

Relationship between the diversity of the cagA gene of Helicobacter pylori and gastric cancer in Okinawa, Japan

Editorial

Recurrent acute pancreatitis: is it possible to exclude chronic pancreatitis?

Review

Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits